Progress in targeted inhibition of aerobic glycolysis combined with immunotherapy for renal cell carcinoma
Tumor aerobic glycolysis is one of the main features of tumor metabolic reprogramming. This abnormal glycolytic metabolism provides bioenergy and biomaterials for tumor growth and proliferation. It is worth noting that aerobic glycolysis will not only provide biological materials and energy for tumor cells, but also help tumor cells to escape immune surveillance through regulation of immune microenvironment, thereby resisting tumor immunotherapy and promoting tumor progression. Based on the pathogenesis of renal cell carcinoma, this paper describes the characteristics of aerobic glycolysis, the effect of glycolytic metabolism on the immune microenvironment of renal cell carcinoma, the effect of glycolysis inhibitors on the immune microenvironment of renal cell carcinoma, and the prospect of glycolysis inhibitors combined with immune checkpoint inhibitors in the treatment of renal cell carcinoma.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology - 40(2024), 1 vom: 20. Jan., Seite 74-79 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Zhang, Kun [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.01.2024 Date Revised 23.01.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM367366770 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367366770 | ||
| 003 | DE-627 | ||
| 005 | 20240123232026.0 | ||
| 007 | tu | ||
| 008 | 240122s2024 xx ||||| 00| ||chi c | ||
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM367366770 | ||
| 035 | |a (NLM)38246180 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Zhang, Kun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Progress in targeted inhibition of aerobic glycolysis combined with immunotherapy for renal cell carcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2024 | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Tumor aerobic glycolysis is one of the main features of tumor metabolic reprogramming. This abnormal glycolytic metabolism provides bioenergy and biomaterials for tumor growth and proliferation. It is worth noting that aerobic glycolysis will not only provide biological materials and energy for tumor cells, but also help tumor cells to escape immune surveillance through regulation of immune microenvironment, thereby resisting tumor immunotherapy and promoting tumor progression. Based on the pathogenesis of renal cell carcinoma, this paper describes the characteristics of aerobic glycolysis, the effect of glycolytic metabolism on the immune microenvironment of renal cell carcinoma, the effect of glycolysis inhibitors on the immune microenvironment of renal cell carcinoma, and the prospect of glycolysis inhibitors combined with immune checkpoint inhibitors in the treatment of renal cell carcinoma | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Ru, Mengyao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiayuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jumei |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Lan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology |d 2003 |g 40(2024), 1 vom: 20. Jan., Seite 74-79 |w (DE-627)NLM148235522 |x 1007-8738 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2024 |g number:1 |g day:20 |g month:01 |g pages:74-79 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2024 |e 1 |b 20 |c 01 |h 74-79 | ||